Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
about
Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 DiabetesEvolution of β-Cell Replacement Therapy in Diabetes Mellitus: Islet Cell TransplantationResolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.FEM-based oxygen consumption and cell viability models for avascular pancreatic islets.Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation.The synergistic effect of Tautomycetin on Cyclosporine A-mediated immunosuppression in a rodent islet allograft model.Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantationCellular and molecular targeting for nanotherapeutics in transplantation tolerance.Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation.PLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes.Assessing the effect of immunosuppression on engraftment of pancreatic islets.Thrombosis and inflammation in intraportal islet transplantation: a review of pathophysiology and emerging therapeutics.Advancing islet transplantation: from engraftment to the immune response.Clinical application of regulatory T cells in type 1 diabetes.Recent progress in pancreatic islet transplantation.Extrahepatic islet transplantation with microporous polymer scaffolds in syngeneic mouse and allogeneic porcine modelsImpact of islet size on pancreatic islet transplantation and potential interventions to improve outcome.Quantitative assessment of islet cell products: estimating the accuracy of the existing protocol and accounting for islet size distribution.AEB071 (sotrastaurin) does not exhibit toxic effects on human islets in vitro, nor after transplantation into immunodeficient mice.Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro.
P2860
Q28552483-F392C215-1D16-4028-BF44-02D4627E8078Q30430239-20195B0C-6B9A-49C1-B0C7-96EBE02BA55AQ30437086-2462E894-4C71-4A5A-A2F8-CB71C9DA4492Q30487439-24B93144-18C3-4D3D-BD02-A45DDF0E8C92Q33344421-86FAC09A-DB6D-4B72-A6C5-4E9B1B0FA44DQ33959144-7A8CCC83-420F-497A-A327-5D23DDF884DEQ34506806-DE7A8D44-6FF3-4BBD-A0A7-595234CF06E3Q36011368-4DA0C640-665B-4B63-BC32-30FC9339EF31Q36327666-47F75E53-8841-4A51-A262-982D2ED272D1Q36801593-A1213EB8-4FC9-4F1D-8A5A-0D6B3BC52DA4Q37206838-446BA93A-76EE-4FD2-A694-82632999C921Q37404257-85E1078A-70E5-4F7A-83DC-E862DF54D5B8Q37914776-10373864-2100-4A91-8666-4DE155B97F31Q38102783-EA9E25CE-971B-4895-8047-0186681916CCQ38156830-89961E85-09BE-4F21-8977-E95F5CE543C7Q38739608-2EEE5717-21B7-4E8C-ABCB-F862549E1273Q40505974-66AC15E5-3171-4DD1-9409-3C59E7DAAC40Q47172489-D2DD8210-8C9D-42E9-855D-D809AEB22A52Q51367878-687B36D2-E289-45E2-8C48-4BFF12AA040AQ53478295-2121879A-B389-449A-8D46-20C8669499D5
P2860
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
@ast
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
@en
type
label
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
@ast
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
@en
prefLabel
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
@ast
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
@en
P1433
P1476
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
@en
P2093
A M James Shapiro
Sulaiman A Nanji
P304
P356
10.2165/00063030-200418050-00004
P577
2004-01-01T00:00:00Z
P6179
1009303567